GlassScriptPhysician profile
Ann C Beers
NPI 1760439954
$5,870.00
in general payments reported to CMS, 2019-2025
43 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $531 · 2021: $518 · 2022: $749 · 2023: $489 · 2024: $1,282 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,930.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $836.71 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $592.38 | 2019-2025 | Tepezza, Repatha, Repatha |
| Medtronic Minimed, INC. | $511.03 | 2019-2020 | |
| Novo Nordisk INC | $478.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $269.79 | 2021-2025 | Minimed 780g |
| Lilly USA, LLC | $265.41 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $244.33 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $235.99 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $215.88 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $193.41 | 2019-2025 | |
| Abbvie INC. | $185.45 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $175.80 | 2024-2025 | Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.48 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $148.90 | 2023-2025 | |
| Abbott Laboratories | $120.05 | 2019-2025 | Freestyle Libre 3 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Beers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.